2018-04-20 |
1 |
|
United States Patent Nos. 9,526,734 (“the ’734
patent”), 9,649,318 (“the ’318 patent”), and 9,808,468…734, ’318, and ’468
patents no later than when each patent was issued by the Patent Office and/or listed…
expiration date of the ’734 patent, the ’318 patent, or the ’468 patent, as extended by any
applicable…to the expiration of the ’734 patent, the ’318 patent, or the ’468 patent, as extended
…to the expiration of the ’734 patent, the ’318 patent, or the ’468 patent, as extended
by any applicable |
External link to document |
2020-01-21 |
108 |
Patent/Trademark Report to Commissioner of Patents |
the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,526,734; 9,649,318; 9,808,468…2018
22 January 2020
1:18-cv-00599
835 Patent - Abbreviated New Drug Application(ANDA)
Plaintiff |
External link to document |
2018-04-20 |
4 |
|
the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,526,734; 9,649,318; 9,808,468…2018
22 January 2020
1:18-cv-00599
835 Patent - Abbreviated New Drug Application(ANDA)
Plaintiff |
External link to document |
2019-09-23 |
97 |
Order - -Memorandum and Order |
States Patent
Nos. 9,526,734 (the "#734 patent"), 9,649,318 (the "#318 patent"),…9,808,468
(the "#468 patent"). D.I. 1 at ,r 1. The asserted patents cover Plaintiffs'
VIVLODEX…10mg, before the expiration of the" asserted patents. D.I. 76 at 1.
The deadline for leave to…counterclaims, seeking to
assert that the asserted patents are invalid as indefinite under 35 U.S.C. § 112…2018
22 January 2020
1:18-cv-00599
835 Patent - Abbreviated New Drug Application(ANDA)
Plaintiff |
External link to document |